Abstract
SARS-CoV-2 has evolved rapidly towards higher infectivity and partial immune escape over the course of the pandemic. This evolution is driven by the enormous virus population, that has infected close to 200 million people by now. Therefore, cost effective and scalable methods are needed to monitor viral evolution globally. Mutation-specific PCR approaches have become inadequate to distinguish the variety of circulating SARS-CoV-2 variants and are unable to detect novel ones. Conversely, whole genome sequencing protocols remain too labor- and cost-intensive to monitor SARS-CoV-2 at the required density. By adapting SARSeq we present a simple, fast, and scalable S-gene tiling pipeline for focused sequencing of the S-gene encoding for the spike protein. This method reports on all sequence positions with known importance for infectivity and immunity, yet scales to >20K samples per run. S-gene tiling is used for nationwide surveillance of SARS-CoV-2 at a density of 10% to 50% of all cases of infection in Austria. SARSeq S-tiling uncovered several infection clusters with variants of concern such as the biggest known cluster of Beta/B.1.351 outside Africa and successfully informed public health measures in a timely manner, allowing their successful implementation. Our close monitoring of mutations further highlighted evolutionary constraints and freedom of the spike protein ectodomain and sheds light on foreseeable evolutionary trajectories.
Competing Interest Statement
U.E., L.C., A.S. and R.Y. declare the following competing interest: A European patent application EP 20202627.4 was filed on Oct. 19., 2020. We will, however, grant non-exclusive licenses for all non-commercial use. U.E. consults for Tango Therapeutics and is a co-founder of JLP Health. All other authors declare no competing interests.
Funding Statement
Curiosity driven biomedical research at the IMP is largely sponsored by Boehringer Ingelheim. IMBA is generously funded by the OEAW.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study involves the use of patient medical data from EMS (Epidemiologisches Meldesystem), which is the official source for public health surveillance activities in Austria. EMS follows the mandate of Austrian and international legislation and is hosted by the Austrian Agency for Health and Food Safety (AGES). The present study was approved by the local Ethics Committee of Vienna (#EK 21-141-0721) and the Federal Office for Safety and Health Care (BASG). Sequencing and analyses of virus whole genomes were approved by the Ethics Committee of the Medical University of Vienna, Austria (2283/2019). The study was conducted in accordance with the Declaration of Helsinki.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Custom code was used to analyze all NGS data. The script is available at GitHub under https://github.com/sarseq/sarseq2.
